2025-01-01 2025-12-31 2025-12-31 true 15342017 Therapy DOG Training UK Ltd 85590Other education not elsewhere classified iso4217:GBP xbrli:pure 153420172025-01-01 153420172025-12-31 153420172025-01-01 2025-12-31 15342017bus:SmallEntities2025-01-01 2025-12-31 15342017bus:AuditExempt-NoAccountantsReport2025-01-01 2025-12-31 15342017bus:FullAccounts2025-01-01 2025-12-31 15342017core:WithinOneYear2025-12-31 15342017core:AfterOneYear2025-12-31 15342017core:WithinOneYear2025-01-01 2025-12-31 15342017core:AfterOneYear2025-01-01 2025-12-31 15342017core:CurrentFinancialInstruments2025-12-31 15342017core:Non-currentFinancialInstruments2025-12-31 15342017core:CurrentFinancialInstruments2025-01-01 2025-12-31 15342017core:Non-currentFinancialInstruments2025-01-01 2025-12-31 15342017core:LandBuildings2025-01-01 2025-12-31 15342017core:FurnitureFittings2025-01-01 2025-12-31 15342017core:OfficeEquipment2025-01-01 2025-12-31 15342017core:Vehicles2025-01-01 2025-12-31 15342017core:PlantMachinery2025-01-01 2025-12-31 15342017core:OtherPropertyPlantEquipment2025-01-01 2025-12-31 15342017core:LandBuildings2025-12-31 15342017core:PlantMachinery2025-12-31 15342017core:Vehicles2025-12-31 15342017core:FurnitureFittings2025-12-31 15342017core:OfficeEquipment2025-12-31 15342017core:OtherPropertyPlantEquipment2025-12-31 15342017core:Right-of-useAssets2025-01-01 2025-12-31 15342017core:Right-of-useAssets2025-12-31 15342017core:Goodwill2025-01-01 2025-12-31 15342017core:PatentsTrademarksLicencesConcessionsSimilar2025-01-01 2025-12-31 15342017core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-01-01 2025-12-31 15342017core:OtherResidualIntangibleAssets2025-01-01 2025-12-31 15342017core:Goodwill2025-12-31 15342017core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-12-31 15342017core:PatentsTrademarksLicencesConcessionsSimilar2025-12-31 15342017core:OtherResidualIntangibleAssets2025-12-31 15342017dpl:CostSales2025-01-01 2025-12-31 15342017dpl:AdministrativeExpenses2025-01-01 2025-12-31 15342017dpl:DistributionCosts2025-01-01 2025-12-3115342017core:ShareCapital2025-12-31 15342017core:SharePremium2025-12-31 15342017core:RevaluationReserve2025-12-31 15342017core:OtherReservesSubtotal2025-12-31 15342017core:ShareCapitalPreferenceShares2025-12-31 15342017core:CapitalRedemptionReserve2025-12-31 15342017core:OtherCapitalReserve2025-12-31 15342017core:RetainedEarningsAccumulatedLosses2025-12-3115342017core:ShareCapital2025-01-01 2025-12-31 15342017core:SharePremium2025-01-01 2025-12-31 15342017core:RevaluationReserve2025-01-01 2025-12-31 15342017core:OtherReservesSubtotal2025-01-01 2025-12-31 15342017core:RetainedEarningsAccumulatedLosses2025-01-01 2025-12-311534201712025-01-01 2025-12-31 1534201722025-01-01 2025-12-3115342017core:ShareCapital12025-01-01 2025-12-31 15342017core:ShareCapital22025-01-01 2025-12-3115342017core:SharePremium12025-01-01 2025-12-31 15342017core:SharePremium22025-01-01 2025-12-3115342017core:RevaluationReserve12025-01-01 2025-12-31 15342017core:RevaluationReserve22025-01-01 2025-12-3115342017core:RetainedEarningsAccumulatedLosses12025-01-01 2025-12-31 15342017core:RetainedEarningsAccumulatedLosses22025-01-01 2025-12-311534201712025-01-01 2025-12-3115342017core:Non-currentFinancialInstrumentscore:CostValuation2025-01-01 15342017core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-12-31 15342017core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-12-3115342017core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-12-31 15342017core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2025-12-31 15342017core:Non-currentFinancialInstrumentscore:CostValuation2025-12-3115342017core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-01-01 15342017core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-12-31 15342017core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-12-31 15342017core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-12-31 15342017core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2025-12-31 15342017core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-12-31 15342017core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-12-3115342017core:Non-currentFinancialInstruments2025-12-31 15342017core:Non-currentFinancialInstruments2024-12-31153420172023-12-11 153420172024-12-31 153420172023-12-11 2024-12-31 15342017core:WithinOneYear2024-12-31 15342017core:AfterOneYear2024-12-31 15342017core:CurrentFinancialInstruments2024-12-31 15342017core:Non-currentFinancialInstruments2024-12-31 15342017core:LandBuildings2024-12-31 15342017core:PlantMachinery2024-12-31 15342017core:Vehicles2024-12-31 15342017core:FurnitureFittings2024-12-31 15342017core:OfficeEquipment2024-12-31 15342017core:OtherPropertyPlantEquipment2024-12-31 15342017core:Right-of-useAssets2024-12-31 15342017core:Goodwill2024-12-31 15342017core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-31 15342017core:PatentsTrademarksLicencesConcessionsSimilar2024-12-31 15342017core:OtherResidualIntangibleAssets2024-12-31 15342017dpl:AdministrativeExpenses2023-12-11 2024-12-3115342017core:ShareCapital2024-12-31 15342017core:SharePremium2024-12-31 15342017core:RevaluationReserve2024-12-31 15342017core:OtherReservesSubtotal2024-12-31 15342017core:ShareCapitalPreferenceShares2024-12-31 15342017core:CapitalRedemptionReserve2024-12-31 15342017core:OtherCapitalReserve2024-12-31 15342017core:RetainedEarningsAccumulatedLosses2024-12-3115342017core:RetainedEarningsAccumulatedLosses2023-12-11 15342017core:ShareCapital2023-12-11 15342017core:SharePremium2023-12-11 15342017core:RevaluationReserve2023-12-11 15342017core:ShareCapital2023-12-11 2024-12-31 15342017core:SharePremium2023-12-11 2024-12-31 15342017core:RevaluationReserve2023-12-11 2024-12-31 15342017core:OtherReservesSubtotal2023-12-11 2024-12-31 15342017core:RetainedEarningsAccumulatedLosses2023-12-11 2024-12-311534201712023-12-11 2024-12-31 1534201722023-12-11 2024-12-3115342017core:ShareCapital12023-12-11 2024-12-31 15342017core:ShareCapital22023-12-11 2024-12-3115342017core:SharePremium12023-12-11 2024-12-31 15342017core:SharePremium22023-12-11 2024-12-3115342017core:RevaluationReserve12023-12-11 2024-12-31 15342017core:RevaluationReserve22023-12-11 2024-12-3115342017core:RetainedEarningsAccumulatedLosses12023-12-11 2024-12-31 15342017core:RetainedEarningsAccumulatedLosses22023-12-11 2024-12-3115342017bus:Director12025-01-01 2025-12-3115342017bus:Director22025-01-01 2025-12-3115342017bus:PrivateLimitedCompanyLtd2025-01-01 2025-12-31
Therapy DOG Training UK Ltd
Dormant Financial Statements
for the year ended 31 December 2025
Company registration number 15342017
(England and Wales)

Company Information

For the year ended 31 December 2025
Directors Lincoln, Carol
Ellis, Sarah Denise

Registered office 2 Manor Daf Gardens
St. Clears
Carmarthen
SA33 4ES

Registered number 15342017

Accountant 2020 ACCOUNTANCY
Bourne Space
Bourne House
23 Hinton Road
Bournemouth
Bournemouth
BH1 2EF

Statement of Financial Position

As at 31 December 2025
Notes
2025
2024
£
£
£
£
Current assets
Debtors
4
2
2
2
2
Net current assets (liabilities)
2
2
Total assets less current liabilities
2
2
Net assets (liabilities)
2
2
Capital and reserves
Called up share capital
2
2
Total equity
2
2

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 15 September 2026 and are signed on its behalf by:

Lincoln, Carol
Lincoln, Carol
Director
Ellis, Sarah Denise
Ellis, Sarah Denise
Director

Company registration number 15342017

Notes to the Financial Statements

For the year ended 31 December 2025

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

3. Employees

The average number of employees during the year was 0 (2024: 0).

4. Debtors

2025
2024
£
£
Directors loan accounts
2
2
Total due within one year
2
2
Total due after one year
-
-
Total
2
2